{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:05Z","timestamp":1791409805984,"version":"4.3.3"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.012","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:17:38Z","timestamp":1790007458000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of nonstatin LDL-cholesterol-lowering therapies: A systematic review and pairwise meta-analysis of randomized controlled trials"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8831-6178","authenticated-orcid":false,"given":"Andrea","family":"Matteucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aquilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacl.2026.09.012_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.012_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.012_bib3","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.012_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.jacl.2026.09.012_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"10106","key":"10.1016\/j.jacl.2026.09.012_bib6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.012_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3\u20135\u2009years of placebo-controlled observation in the ODYSSEY OUTCOMES trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.jacl.2026.09.012_bib8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib9","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jacl.2023.10.011","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","volume":"18","author":"Bays","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","article-title":"Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"De Filippo","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2026.09.012_bib12","first-page":"229","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors and neurocognitive safety: a meta-regression analysis of randomized controlled trials","volume":"328","author":"Raccah","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2026.09.012_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.09.012_bib14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.09.012_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.012_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.012_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.012_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jacl.2026.09.012_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.012_bib20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1253\/circj.CJ-25-0089","article-title":"Efficacy and safety of bempedoic acid in Japanese patients with hypercholesterolemia - a randomized, double-blind, placebo-controlled phase 3 study (the CLEAR-J trial)","volume":"89","author":"Yamashita","year":"2025","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.012_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagn\u00e9","year":"2002","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.012_bib22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.012_bib23","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.09.012_bib24","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.012_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.012_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.012_bib27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.012_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.012_bib29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2026.09.012_bib30","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12944-015-0036-z","article-title":"A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia","volume":"14","author":"Saito","year":"2015","journal-title":"Lipids Health Dis"},{"issue":"9858","key":"10.1016\/j.jacl.2026.09.012_bib32","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"issue":"9858","key":"10.1016\/j.jacl.2026.09.012_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacl.2026.09.012_bib34","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacl.2026.09.012_bib35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.012_bib36","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacl.2026.09.012_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.012_bib38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.012_bib39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.012_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"issue":"43","key":"10.1016\/j.jacl.2026.09.012_bib41","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2026.09.012_bib42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"9965","key":"10.1016\/j.jacl.2026.09.012_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.012_bib44","first-page":"1073","article-title":"Efficacy and safety of evolocumab in Japanese patients with dyslipidemia (YUKAWA-2): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"79","author":"Teramoto","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.09.012_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.012_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003421","article-title":"ODYSSEY CHOICE II Investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.012_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dL or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.012_bib48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.09.012_bib49","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.012_bib50","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"issue":"15","key":"10.1016\/j.jacl.2026.09.012_bib51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Kastelein","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.012_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"16","key":"10.1016\/j.jacl.2026.09.012_bib54","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.012_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-Mono randomized clinical trial","volume":"86","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.012_bib56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jjcc.2018.10.004","article-title":"Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON","volume":"73","author":"Teramoto","year":"2019","journal-title":"J Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.012_bib57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"10529","key":"10.1016\/j.jacl.2026.09.012_bib58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.09.012_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:19Z","timestamp":1791406819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S1933287426005234"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of nonstatin LDL-cholesterol-lowering therapies: A systematic review and pairwise meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}